KANCHIKanchi Karpooram Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-10-28 (delayed ~30 min in market hours)
Kanchi Karpooram Limited engages in the manufacture and sale of camphor and allied products in India. The company operates through two segments, Camphor and Trading of Agro Products. It provides camphene, dipentene, isoborneol, isobornyl acetate, sodium acetate trihydrate, pine pitch, double distilled turpentine, pine tar, pine oil, gum rosin, value added resins, fortified rosin, and ester gum. The company is also involved in the trading of raw cashew nuts and other agro products. It serves tyres, paint, paper, food, pharma, rubber, fragrance, and other industries. The company was incorporated in 1992 and is based in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on KANCHI — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 38/100)
- • ROE: 2.4%
- • ROCE: 1.9%
- • MACD: bearish
- • Price vs EMA21: below
Bull case
- • Revenue growth: 16.4% YoY
- • Profit growth: 112.9% YoY
- • Debt/Equity: 0.00
- • Volume trend: 1.6x baseline
Bear case
- • ROE: 2.4%
- • ROCE: 1.9%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • ROE: 2.4%
- • ROCE: 1.9%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹18.26). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.